New drug combo targets Hard-to-Treat leukemia
NCT ID NCT07411586
First seen Feb 26, 2026 · Last updated Jun 21, 2026 · Updated 19 times
Summary
This early-phase trial tests two oral drugs, olutasidenib and ziftomenib, together in 20 adults with a specific form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The first part finds a safe dose; the second checks if that dose helps control the disease. The study focuses on people whose leukemia has mutations in both the NPM1 and IDH1 genes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Olutasidenib and ziftomenib (oral drugs)
What this could lead to
If successful, this could lead to a new treatment option for people with a specific type of AML that has not responded to standard therapy.
What could go wrong
This is an early, small trial (20 people) focused on safety and dosing, so it may not show clear benefit. Side effects from the drug combination are possible and not yet fully known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.